Visualize alpha-emitting radiopharmaceuticals in vivo with advanced Alpha-SPECT™ imaging technology.
Targeted alpha therapies offer significant potential in oncology, but characterizing their biodistribution, tumor targeting, and retention presents unique challenges. Conventional imaging approaches can limit researchers’ ability to directly visualize alpha-emitting radionuclides and understand their behavior over time.
Perceptive Discovery’s α-Sight platform enables direct in vivo imaging of alpha-emitting radiopharmaceuticals using high-sensitivity Alpha-SPECT™ Mini technology. Integrated with quantitative image analysis through VivoQuant, this approach provides spatial and longitudinal insights to inform targeted alpha therapy development.
What You’ll Learn
Download our α-Sight flyer to explore:
- Direct alpha-emitter imaging: Visualizing Ac-225 and At-211 therapies using advanced CZT-based SPECT technology.
- Longitudinal biodistribution analysis: Monitoring radiopharmaceutical distribution and retention in the same animal over multiple time points.
- Multi-isotope detection: Imaging Ac-225 and daughter radionuclides across multiple energy windows.
- Quantitative image analysis: Integrating Alpha-SPECT imaging with CT co-registration, gamma counting, and VivoQuant analysis.
- Improved candidate evaluation: Supporting compound screening, tumor targeting validation, and pharmacokinetic and pharmacodynamic assessment.
The flyer also presents preclinical imaging data demonstrating longitudinal visualization of an Ac-225-labeled antibody and its daughter radionuclides.